Parag Parikh Flexi Cap: Midcap and Smallcap Picks Reviewed
In my previous post, we saw that Parag Parikh Flexi Cap (PPFAS) is mostly a largecap fund, in both its Indian and international exposure, with very limited allocation to Indian midcaps and smallcaps. In this post, we look at the midcap and smallcap bets the fund has made over the past two years (since September 2024), a period when the market has been mostly flat or down.
What they bought
Comparing PPFAS’s monthly portfolio disclosures from September 2024 and September 2026, the following midcaps and smallcaps were added:
Company | Month First Invested | Avg. Buy Price (₹) | Price on 15 Nov 2026 (₹) | % Change |
Narayana Hrudayalaya Limited | Dec-24 | 1,313 | 1,855 | 41.3% |
Nesco Limited | May-25 | 1,019 | 1,052 | 3.2% |
Indus Towers Limited | Nov-25 | 376 | 391 | 4.0% |
CIE Automotive India Limited | Jan-26 | 391 | 379 | -3.1% |
CMS Info Systems Limited | Jan-26 | 291 | 215 | -26.1% |
Mahanagar Gas Limited | Feb-26 | 1,101 | 1,143 | 3.8% |
Petronet LNG Limited | Jun-26 | 285 | 328 | 15.1% |
Average buy price is the average of the month-end prices across all months in which PPFAS bought the stock between September 2024 and September 2026. PPFAS does not disclose its exact purchase prices, so month-end prices are used as a proxy.
Parag Parikh Flexicap has added seven midcaps and smallcaps (this excludes any companies added after September 2024 and exited before September 2026). Narayana Hrudayalaya has been the best performer of the lot, up 41.3%, and has been in the portfolio for almost two years. Petronet LNG, up 15.1%, is the only other stock with double-digit returns, and it is also the largest of these seven investments.
The rest have not delivered substantial gains. Nesco, Indus Towers and Mahanagar Gas are up by about 3–4%, CIE Automotive is marginally down (-3.1%), and CMS Info Systems is the only one in a consistent decline since PPFAS started investing (-26.1%). Taking an XIRR across these seven investments over the last two years gives roughly 10%, against roughly 6% for a SIP in the Nifty Midcap 150 index over the same period.
The 10% XIRR is weighted by the size and date of each investment. It is still an estimate rather than a precise figure: PPFAS does not disclose its purchase prices, so I have used month-end closing prices, and the fund may well have paid more or less than that during the month it bought. Even so, it suggests the midcap and smallcap bets have at least kept up with the midcap index, and possibly beaten it. None of these stocks has seen wild price swings, and the fund appears to have favoured value-oriented companies.
What they sold
PPFAS also sold seven midcaps and smallcaps that it held in September 2024. Six are shown below, with the month in which PPFAS first started selling rather than the month of full exit:
Company | Sell Start Month | Price in Sept 2024 (₹)* | Price in Month First Sold (₹)* | Price on 15 Nov 2026 (₹) | % Change After Selling Started |
Motilal Oswal Financial Services | Oct-24 | 761 | 923 | 1,220 | 32.2% |
MCX | Oct-24 | 1,132 | 1,276 | 3,725 | 191.9% |
UTI AMC | Oct-24 | 1,252 | 1,336 | 835 | -37.5% |
IPCA Laboratories | Jan-25 | 1,496 | 1,443 | 1,885 | 30.6% |
NMDC | Feb-25 | 81.54 | 74.61 | 69.90 | -6.3% |
Balkrishna Industries | Feb-26 | 3,064 | 2,515 | 2,271 | -9.7% |
Note:
1. Accelya Solutions was also completely exited during this period, but PPFAS’s investment in it was very small in September 2024, so it has not been considered.
2. *The price taken is price as of month end
The exits tell an interesting story.
IPCA Laboratories: PPFAS had exited completely by August 2025, and the stock gained considerably after November 2025.
Motilal Oswal: PPFAS sold steadily and exited completely in May 2025. The stock fell sharply between January and May 2025, to as low as ₹625, and in May, when most of the remaining stake was sold, its highest price for the month was ₹809. Hence its average selling price would be considerably lower than ₹800. With the stock now at ₹1,220, it looks as though PPFAS sold at a low and would have been better off holding.
NMDC: Selling looks like a good decision. For most of the two-year period, however, the stock traded around the price at which PPFAS started selling, with a high of ₹95-plus. The recent fall reflects the broader softening of metal prices.
MCX: PPFAS exited completely in January 2026. This looks like a clear missed opportunity, as MCX has gained steadily over the two years.
Balkrishna Industries: The stock declined steadily from September 2024 to January 2026 and has stayed volatile since.
What stands out is that IPCA, Motilal Oswal and MCX gained considerably after PPFAS began selling, while UTI AMC and Balkrishna have declined steadily since. NMDC would have been at a slight loss, given the pressure on metal and mining stocks from softer metal prices. Overall, had PPFAS retained all of its holdings in these six stocks, the size and appreciation of IPCA, Motilal Oswal and MCX would have left it with a net gain.
Key takeaway
The buying and selling suggest PPFAS has no trouble identifying good-quality companies in the midcap and smallcap space, even if the exits were not always well timed. What it has not produced are multibaggers: other active midcap, smallcap and flexicap funds have held stocks that went 2x, 3x or even 4x in this same two-year period, and PPFAS only had MCX with that potential, but sold it too soon. Instead, its picks look like steady compounders. The recent additions have at least kept pace with the midcap index, while three of the six stocks it sold (IPCA, Motilal Oswal and MCX) have done well since. The real issue is size: the allocation is too small to make a meaningful difference to the fund’s overall performance.
So, as of now, PPFAS offers:
1. Largecap stability
2. International diversification
3. Midcap and smallcap compounders
If it took larger positions in its best ideas, or found more compounders, it would become a more well-rounded flexicap fund.
Source: Parag Parikh monthly portfolio disclosures (holdings); moneycontrol.com (stock prices).
This is my personal analysis and is not investment advice.
Disclaimer: Nothing in this article is a solicitation, recommendation, endorsement or offer. Past performance of an index, asset class, individual mutual fund scheme or stocks is no guarantee of future performance as to returns and risks. We do not take any responsibility for investment decisions based on this article. Please consult your advisor before taking any decisions on your portfolio construction. Registration granted by SEBI, BASL membership, and NISM certification do not guarantee the intermediary’s performance or provide any assurance of returns to investors. Investment in the securities market is subject to market risks. Read all the related documents carefully before investing.




Comments